Global Pancreatic Cancer Therapeutics Market
Pancreatic cancer is the disease characterized by the abnormal proliferation of tumor cells in the pancreas leads to hinder in the pancreas function. Pancreatic cancer is majorly classified into 2 types namely exocrine cancers and neuroendocrine cancers. Symptoms associated with the pancreas cancer include jaundice, weight loss, abdominal pain, and diarrhea. Pancreatic cancer mainly occurs due to the consumption of tobacco and alcohol, smoking, obesity, and family history of pancreatitis. Pancreatic cancer can be diagnosed by using the MRI, CT scan, and ultrasound techniques and can be prevented by chemotherapy, radiotherapy, and surgery.
Increase in the alcohol and tobacco consumption, a rise in the government funding for the R&D activities, growing prevalence of pancreatic cancer diseases, and promising pipeline drugs for the pancreatic cancer treatment are anticipated to propel the pancreatic cancers market growth over the forecast period. Furthermore, rise in obesity population, family history of pancreatitis, huge investment by the companies for the development of newer drugs expected to drive the Global Pancreatic Cancer Therapeutics Market over the forecast period. However, stringent regulatory policies, difficulty in early-stage disease diagnosis, the high cost of the treatment, adverse effects associated with the drugs, and lesser drugs available for the treatment might hamper the growth of Global Pancreatic Cancer Therapeutics Market.
Pancreatic cancer therapeutics market is segmented on the basis of disease type, treatment type, and end user
Based on the treatment type, pancreatic cancer therapeutics market is segmented into the following:
- Alkylating agents
- Natural products
- Targeted therapy
Based on the disease type, pancreatic cancer therapeutics market is segmented into the following:
- Exocrine pancreas cancer
- Exocrine pancreas cancer
Based on the distribution channel, Global Pancreatic Cancer Therapeutics Market is segmented into the following:
- Hospital pharmacies
- Retail Pharmacies
- Online pharmacies
Global Pancreatic Cancer Therapeutics Market is growing at a significant CAGR owing to increase in the prevalence of pancreatic cancer and increase in R&D activities for the innovation of newer therapeutics. Increase in the government funding and huge investments from the private sector for R&D activities is anticipated to propel the market growth. Acquisitions & mergers, collaborations, product pipeline are the key factors driving the market players revenue growth in Global Pancreatic Cancer Therapeutics Market. For instance, in December 2015, Boehringer Ingelheim collaborated with MD Andersen Cancer Centre for the development of newer therapeutics for pancreatic cancer. Similarly, in September 2013, Celgene received FDA approval for Abraxane used for the treatment of pancreatic cancer.
Geographically, Global Pancreatic Cancer Therapeutics Market is segmented into the Europe, Latin America, Asia Pacific, the Middle East and Africa, and North America. North America pancreatic cancer therapeutics market is growing at a significant rate due to increase in the prevalence of pancreatic cancer majorly in U.S. (according to NIH 2014, about 64,668 people diagnosed with pancreatic cancer). In addition, high adoption of pancreatic therapeutics, increase in healthcare expenditure, and rise in R&D activities are propelling the pancreatic cancer therapeutics market in North America. In Europe region, rise in the prevalence of pancreatic cancer majorly in Germany, Finland, Austria, U.K and other Europe countries (according to Cancer Research UK 2014, about 9,600 new pancreatic cancer cases in the UK and 8,817 people died of the disease), and developed healthcare infrastructure boost the Global Pancreatic Cancer Therapeutics Market. However, Asia Pacific is an emerging region for pancreatic cancer therapeutics market owing to increase in R&D expenditure rise in geriatric and obese population, growing healthcare expenditure are expected to fuel the market over the forecast period.
Some of the players in pancreatic cancer therapeutics market are F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Pfizer, Inc. (U.S.), Eli Lilly and Company (U.S.), Boehringer Ingelheim GmbH (Germany), Celgene Corporation (U.S.), Amgen, Inc. (U.S.), Tempus, Inc. (U.S.), and Ipsen (France) to name a few.
- In January 2017, Tempus and University of Michigan collaborated to for the development of novel pancreatic cancer therapeutics
- In March 2017, Ipsen acquired the Inivyde (Irinotecan liposome), a pancreatic cancer therapeutic drug from Merrimack Pharmaceuticals for expanding the oncology portfolio
- The report provides granular level information about the market size, regional market share, and forecast from 2017-2023
- The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments, and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario